Two of the major global pharmaceutical CDMOs, Lonza and Alcami, have announced the appointments of new CEOs in early June. There have also been changes in senior positions at Corden Pharma and, imminently, at Cambrex.

The DuPont board of directors has reappointed Edward Breen as CEO in addition to his role as executive chairman, following disappointing results in 2019. Breen (above) had been chairman and CEO from 2015 to the merger with Dow, was CEO of DowDuPont until their merger was completed and had taken a board role at Corteva, the split-out crop protection company, since 2019.